Early Treatment of
            <i>Campylobacter jejuni</i>
            Enteritis

Williams, Myra D.; Schorling, John B.; Barrett, Leah J.; Dudley, Sharon M.; Orgel, I; Koch, William C.; Shields, David S.; Thorson, Stephen; Lohr, Jacob A.; Guerrant, Richard L.

doi:10.1128/aac.33.7.1129

Cited by 11 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most immunocompetent individuals, campylobacteriosis is a self-limiting disease, and treatment with antimicrobials reduces the period of fecal shedding but does not have a large impact on the duration of disease symptoms (4,105,180). However, when given early, some clinical benefit has been observed (126,147).…”

Section: Pathology and Pathophysiology Of Campylobacter Infectionmentioning

confidence: 99%

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

et al. 2008

View full text Add to dashboard Cite

SUMMARY Campylobacter is a major cause of acute bacterial diarrhea in humans worldwide. This study was aimed at summarizing the current understanding of host mechanisms involved in the defense against Campylobacter by evaluating data available from three sources: (i) epidemiological observations, (ii) observations of patients, and (iii) experimental observations including observations of animal models and human volunteer studies. Analysis of available data clearly indicates that an effective immune system is crucial for the host defense against Campylobacter infection. Innate, cell-mediated, and humoral immune responses are induced during Campylobacter infection, but the relative importance of these mechanisms in conferring protective immunity against reinfection is unclear. Frequent exposure to Campylobacter does lead to the induction of short-term protection against disease but most probably not against colonization. Recent progress in the development of more suitable animal models for studying Campylobacter infection has opened up possibilities to study the importance of innate and adaptive immunity during infection and in protection against reinfection. In addition, advances in genomics and proteomics technologies will enable more detailed molecular studies. Such studies combined with better integration of host and pathogen research driven by epidemiological findings may truly advance our understanding of Campylobacter infection in humans.

show abstract

Section: Pathology and Pathophysiology Of Campylobacter Infectionmentioning

confidence: 99%

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Treatment is not necessary in all cases, but early treatment is recommended for those patients with moderate to severe symptoms, relapses, or a prolonged course of infection (7). Erythromycin, doxcycline, and, in the last few years, the broad-spectrum fluoroquinolones have been used as oral therapies for these infections (5,18). Moreover, fluoroquinolones have been proposed for use in adults for both the therapy and the prevention of traveler's diarrhea (3).…”

mentioning

confidence: 99%

Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents

Gómez-Garcés

Cogollos

Alos

1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The resistance of Campylobacter jejuni strains to the fluoroquinolones is increasingly frequent, and in our area it reaches nearly 50%. We studied the susceptibilities of 60 of these strains to 11 oral antibiotics. All strains except one were susceptible to the macrolides tested, with azithromycin being the most active agent tested. Of the rest of the antibiotics studied, amoxicillin-clavulanic acid, clindamycin, and fosfomycin displayed good in vitro activities. Knowledge of the susceptibilities of these microorganisms to a varied group of oral agents is necessary in view of the appearance of multiresistant strains, such as those included in our series.

show abstract

“…Enterocolitis due to Campylobacter species is usually a mild to moderate self-limited diarrheal disease; however, patients with severe, prolonged, or relapsing Campylobacter enterocolitis are recommended for treatment with antibiotics. Erythromycin, doxycycline, and, more recently, the new quinolones have been utilized as therapy for these infections (8,11,23). …”

mentioning

confidence: 99%

Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report

Sjögren

Kaijser

Werner

1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Resistance to erythromycin and doxycycline and more recently to fluoroquinolones has been reported to occur in Campylobacter spp. both in vitro and in patients treated with these antibiotics. The frequency of resistance to 14 antimicrobial agents in Campylobacter jejuni and Campylobacter coli isolated from patients infected in Sweden or abroad is described. For some agents, a comparison of susceptibility in strains of Campylobacter spp. isolated in 1978 with those isolated in 1988 is made. No general increase in in vitro resistance to antibiotics commonly used for the treatment of human gastroenteritis caused by C. jejuni or C. coli has occurred during the last 10 years in Sweden, which might be a consequence of strict antibiotic control. The numbers of strains from 1988 to 1989 resistant to ciprofloxacin and to norfloxacin included in this study (0.7 and 1.4%, respectively) are still fewer than those that were resistant to erythromycin (7.3%) or doxycycline (12.4%). There is, however, since 1989 to 1990 an indication of increasing resistance to these antibiotics.

show abstract

Early Treatment of Campylobacter jejuni Enteritis

Abstract: Volume 33, no. 2, p. 248. The byline should read as shown above.

Cited by 11 publications

References 0 publications

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents

Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report

Contact Info

Product

Resources

About